New clinical evidence expands indications for existing classes of drugs. A retrospective cohort study published in BMC Cancer suggests sodium-glucose cotransporter-2 inhibitors (SGLT2i), typically used in type 2 diabetes management, may substantially improve survival rates in endometrial cancer patients. This finding may herald new adjunctive applications for SGLT2i in oncology, offering a potential paradigm shift in treatment protocols for this gynecologic malignancy.